First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

被引：3
|
作者：
Hafner, Susanne [1 ]
机构：
[1] Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
CELL LUNG-CANCER; BEVACIZUMAB; ERLOTINIB; MULTICENTER;
D O I：
10.1038/s41392-021-00813-y
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Wu, Qiang
    Luo, Wuxia
    Li, Wen
    Wang, Ting
    Huang, Lin
    Xu, Feng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Oral Vinorelbine Monotherapy in Patients with EGFR plus NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study
    Kowalski, Dariusz
    Banna, Giuseppe Luigi
    Ramlau, Rodryg
    Ceresoli, Giovanni
    Camerini, Andrea
    Milanowski, Janusz
    Caruso, Michele
    Landreau, Philippe
    Vedovato, Jean-Claude
    Tang, Eng Huat
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1217 - S1218
  • [23] EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Moore, Sara
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1788 - 1792
  • [24] Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380
    Zhang, W.
    Xu, J.
    Lou, Y.
    Zhang, Y.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S236 - S236
  • [25] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [26] Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC
    Zhang, Y.
    Zeng, L.
    Yang, N.
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S363 - S364
  • [27] The first- or second-line use of pemetrexed sequentially with EGFR-TKI did not differ in PFS for advanced NSCLC patients harboring EGFR-mutant tumors.
    Ding, Zhen-Yu
    Chen, Yue-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
    Ng, I.
    Kumarakulasinghe, N.
    Syn, N.
    Teng, R.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2208 - S2209
  • [29] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [30] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
    Cortot, Alexis B.
    Moro-Sibilot, Denis
    Cadranel, Jacques
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
12345